	US 12,221,481 B2
	CD19 binding molecules and uses thereof
Brian Granda, Salisbury, MA (US); Amy Rayo, Cambridge, MA (US); Connie Hong, Somerville, MA (US); Dattananda Chelur, Cambridge, MA (US); Haihui Lu, Winchester, MA (US); Regis Cebe, Saint-Louis (FR); and Sunyoung Jang, Cambridge, MA (US)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on May 19, 2020, as Appl. No. 16/877,878.
Claims priority of provisional application 62/854,695, filed on May 30, 2019.
Claims priority of provisional application 62/850,901, filed on May 21, 2019.
Prior Publication US 2021/0139585 A1, May 13, 2021
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 16/28 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 14/4703 (2013.01); C07K 16/2806 (2013.01); C07K 16/2824 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/522 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01)]

13 Claims

1. A CD19 binding molecule that specifically binds to human CD19 and comprises an antibody or antigen-binding fragment thereof comprising CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19, respectively.